Top Markets
Coin of the day
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation

ADMP
株式のランク #38725
Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company... Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company primarily engaged in the development and commercialization of products within the United States, targeting key therapeutic domains such as allergy, opioid overdose, respiratory conditions, and inflammatory diseases. Its current product portfolio includes SYMJEPI pre-filled epinephrine syringes for the emergency treatment of severe allergic reactions, including anaphylaxis; dry powder inhaler products designed for asthma management; and injectable naloxone for addressing opioid overdose. Additionally, Adamis is advancing pipeline candidates such as APC400, a tempol gel aimed at mitigating radiation-induced dermatitis in cancer patients, and APC410, formulated to treat a range of respiratory ailments including asthma, respiratory syncytial virus (RSV), influenza, and COVID-19. The company also extends its offerings to include corticosteroids, hormone replacement therapies, hospital outsourcing products, and other injectables, alongside a line of veterinary pharmaceutical products. Established in 2006, Adamis Pharmaceuticals Corporation maintains its headquarters in San Diego, California.
株価
$0.6241
最終同期: 2023-10-03
時価総額
$836.88K
変化(1日)
-2.10%
変化(1年)
0.00%
US
取引 Adamis Pharmaceuticals Corporation (ADMP)

カテゴリー

Adamis Pharmaceuticals Corporation(ADMP)の収益
Aug 2026 時点の収益 TTM: 0
Adamis Pharmaceuticals Corporation の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Adamis Pharmaceuticals Corporation の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。